3-Acetylcassain | 59614-18-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3-Acetylcassain
• 英文别名: (3β-acetoxy-7-oxo-14α-methyl-podocarpanylidene-(13seqtrans))-acetic acid-(2-dimethylamino-ethyl ester)；O-Acetyl-cassain；(3β-Acetoxy-7-oxo-14α-methyl-podocarpanyliden-(13seqtrans))-essigsaeure-(2-dimethylamino-aethylester)
• CAS: 59614-18-5
• 化学式: C₂₆H₄₁NO₅
• 分子量: 447.615
• InChiKey: LWUJLWYGXKGVKR-LNPQQOAMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.03
• 重原子数：
  32.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  72.91
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为产物：
  描述：

  咖萨因 、 乙酸酐 在 吡啶 作用下， 生成 3-Acetylcassain
  参考文献：
  名称：

  Recherches sur lesalcaloïdesd'Erythrophleum。12e通讯。Cassamine et erythrophlamine; 几内亚红十字会

  摘要：

  乐fractionnement DES基地extraites德联合国科特迪瓦很多科特迪瓦écorces格木属guineense provenant德扬甘比（省德Stanleyville）一PERMIS D'isoler plusieursalcaloïdescristallisés，拉cassaïne等拉cassaïdine似曾相识connues等德塞夫勒基地其他残疾阙理性avonsappelées cassamine（ C 25 H 39 O 5 N；mp 86-87°； [α] D = -56°）和赤藓胺（C 25 H 39 O 6 N； mp 149-151°[α] D = -62.5°）。

  DOI：

  10.1002/hlca.19490320720

文献信息

• Does smoking increase relapse rates in Graves’ disease?
  作者：L. E. Kimball、E. Kulinskaya、B. Brown、C. Johnston、Nadir R. Farid

  DOI：10.1007/bf03343979

  日期：2002.2

  We wondered whether the relapse rate of Graves' hyperthyroidism was increased amongst patients who smoked. To this end, a retrospective analysis of clinical and laboratory data of consecutive patients with Graves' disease was carried out. All patients were treated with thionamide anti-thyroid drugs (ATD) for at least one year and remission was defined as continued and biochemical euthyroidism, at least 6 months after discontinuing ATD. The study comprised 221 subjects with Graves' disease from a hospital-based population over 9 years. We took the following variables into account when assessing contribution to disease relapse: Goiter, Thyroid Associated Ophthalmopathy (TAO), and Time to euthyroidism after starting ATD and interaction between smoking and sex. Smoking had a marginally significant (p=0.081) deleterious effect on the likelihood of remission after ATD treatment for Graves' disease. The effect of smoking was, however, highly significant in males and indeed the deleterious effect on remissions may be restricted to males (odds ratio, 11.1; 95% confidence interval, 1.25 to 98.5). The presence of goiter (odds ratio, 3.8; 95% confidence interval, 2.05 to 7.1) and TAO (odds ratio, 1.8; 95% confidence interval, 0.993 to 3.18) forecasted lower chances of achieving remission. The shorter the time a patient became euthyroid after starting ATD the more likely his disease was to remit. We conclude that cigarette smoking increases the likelihood of Graves' disease recurrence in males treated with anti-thyroid drugs. Thus, smoking appears to be an important risk factor in the pathogenesis and outcome of Graves' disease patients at least in subsets of patients. (C)2002, Editrice Kurtis.